NasdaqGM:TVTXBiotechs
Does Travere Therapeutics' (TVTX) Streamlined REMS Hint at Lasting Pipeline Momentum?
In early September 2025, Travere Therapeutics announced that the FDA approved updated REMS labeling for FILSPARI, reducing liver function monitoring frequency and removing the embryo-fetal toxicity monitoring requirement, while also sharing positive long-term clinical data from ongoing pegtibatinase studies in classical homocystinuria at an international conference in Japan.
These developments may support improved FILSPARI adoption in IgA nephropathy and highlight steady progress in...